As alluded by another poster, David Haselhurst in Money Magazine June recommends a buy on market for KSX...
He runs through the gist of the technology and suggests that KSX will aim to have a slice of a $15Bil industry that is asthma detection and management... the devices are also reportedly used in management of related pulmonary disorders such as congestive heart failure, sleep apneoa and emphysema...
It seems that the profit margin on the pulmotrack which is scheduled for sale in Q3 this year is 40% (4000 off 10000)...
Good luck to all...
As alluded by another poster, David Haselhurst in Money Magazine...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
